Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time
Guillaume Ploussard(Yves Rocher (France)), Wassim Kassouf(McGill University), Kazumasa Matsumoto(Osaka Research Institute of Industrial Science and Technology), Évanguelos Xylinas(NewYork–Presbyterian Hospital), Tobias Klatte(Helios Hospital Bad Saarow), Luis A. Kluth(Goethe University Frankfurt), Yair Lotan(Southwestern Medical Center), Jonathan I. Izawa(Western University), Ricardo Rendon(Dalhousie University), Adrian Fairey(University of Alberta), Peter C. Black(University of British Columbia), Michael Rink(Marienkrankenhaus Hamburg), Yves Fradet(Centre hospitalier universitaire de Québec), Stephen A. Boorjian(Mayo Clinic), Shahrokh F. Shariat(Universitätszahnklinik Wien), Malte Rieken(NewYork–Presbyterian Hospital), A. Masson-Lecomte(Université Paris Cité), Florian Roghmann(Universitätsklinik Marien Hospital Herne), Alice Dragomir(McGill University), Eiji Kikuchi(Keio University)
Cited by 147
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|793
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786